Overview
Joint Q3 revenue grows 6% to $13.4 mln, slightly beating analyst expectations
Net income improves to $855,000 from a loss of $3.2 mln in Q3 2024
Board authorizes additional $12 mln for share repurchases
Outlook
Company updates 2025 system-wide sales guidance to $530 mln-$534 mln from $530 mln-$550 mln
Comp sales now expected to range from -1% to 0% for 2025
Company maintains 2025 Adjusted EBITDA guidance at $10.8 mln-$11.8 mln
Result Drivers
REFRANCHISING STRATEGY - Co is executing strategies to refranchise its corporate portfolio, aiming to improve financial performance and become a pure-play franchisor
DIGITAL MARKETING - Increased digital marketing efforts, including SEO and AI-search, are part of initiatives to enhance patient acquisition and brand message
TECHNOLOGY INVESTMENT - Co enhanced its mobile app and initiated a three-tiered pricing pilot to improve patient experience and operational efficiency
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Slight Beat*
$13.40 mln
$13.36 mln (5 Analysts)
Q3 EPS
$0.06
Q3 Adjusted EBITDA
$3.30 mln
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Joint Corp is $16.00, about 48.2% above its November 5 closing price of $8.29
The stock recently traded at 31 times the next 12-month earnings vs. a P/E of 36 three months ago
Press Release: ID:nGNX5zT7t8
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)